Assembly Biosciences, Inc.
ASMBAssembly Biosciences, Inc. in brief
Assembly Biosciences, Inc. is a listed company in the Biotechnology industry, based in South San Francisco, California, USA. It was founded in 2005. Its market value was $434 M on 21 October 2026, which makes it the 13,202nd largest listed company in the world and the 2,623rd largest in the USA on this site. In the year to December 2025 it had sales of $72 M and a net loss of $6 M. Jason A. Okazaki is its chief executive. Its shares trade under the symbol ASMB (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Assembly Biosciences, Inc.
Assembly Biosciences is an Ambitious Clinical Stage Biopharmaceutical company. The company annual revenue is 16 million USD and 115 as on 2020. The headquarters is in USA.
Assembly Biosciences, Inc. timeline
- 2005
- 🏁· approximateFounded
- 2008
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2010
- 🔔Initial public offering as Ventrus Biosciences IncFinal prospectus filed with the SEC on 17 December 2010; shares registered for exchange trading on 10 December 2010.
- 2014
- ✎Renamed Assembly Biosciences, Inc.Formerly Ventrus Biosciences Inc.
- 2020
- 💰Record revenue of $79 millionFY2020, the highest of the 7 years on record.
Events of Assembly Biosciences, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,269 (Jan 2020) · #3,237 (Jan 2021) · #4,406 (Jan 2022) · #4,643 (Dec 2022) · #4,632 (Jul 2023) · #4,032 (Jan 2024) · #1,296 (Mar 2026) · #2,509 (Aug 2026) · #2,626 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 6.5×
- Price / book
- 2.1×
- Free cash flow yield
- -9.5%
- Net margin (TTM)
- -16.6%
- Operating margin
- -16.8%
- Return on equity
- -5.4%
- Liabilities / assets
- 19.7%
- Revenue growth
- +153.5%
- R&D / revenue
- 89.6%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $72M | +153.5% | $-12M | $-6M | -8.5% |
| Dec 2024 | $29M | +298.3% | $-45M | $-40M | -140.9% |
| Dec 2023 | $7M | — | $-65M | $-61M | -855.2% |
| Dec 2022 | — | — | $-94M | $-93M | — |
| Dec 2021 | $6M | -92.1% | $-133M | $-130M | -2077.8% |
| Dec 2020 | $79M | +395.6% | $-65M | $-62M | -78.6% |
| Dec 2019 | $16M | +7.8% | $-103M | $-98M | -611.7% |
| Dec 2018 | $15M | — | $-93M | $-91M | -613.2% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-41M | $0M | $-41M | $-0.55 | — |
| Dec 2024 | $-51M | $0M | $-51M | $-6.69 | — |
| Dec 2023 | $23M | $0M | $22M | $-13.38 | — |
| Dec 2022 | $-84M | $0M | $-85M | $-23.08 | — |
| Dec 2021 | $-93M | $3M | $-97M | $-3.00 | — |
| Dec 2020 | $-63M | $0M | $-63M | $-1.75 | — |
| Dec 2019 | $-84M | $2M | $-86M | $-3.72 | — |
| Dec 2018 | $-65M | $0M | $-65M | $-3.98 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $3M (-72.6% on a year earlier), net income $-20M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportResults of operations
- Aug 14, 20268-K/ACurrent report (amended)Results of operations
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 20268-KCurrent reportAcquisition or disposal completed
- Jun 5, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- May 26, 20268-KCurrent reportMaterial agreement · Other events
- May 22, 20268-KCurrent reportRegulation FD disclosure · Other events
- May 7, 202610-QQuarterly report · period to Mar 2026
- May 7, 20268-KCurrent reportResults of operations
- Apr 22, 2026DEF 14AProxy statement
- Mar 30, 20268-KCurrent reportDirectors or officers changed
Official filings of Assembly Biosciences, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $72 M
- Operating income
- $-12 M
- Net income
- $-6 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $258 M
- Total liabilities
- $51 M
- Total equity
- $207 M
As of December-2025
Top 100 institutional investors in Assembly Biosciences, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Gilead Sciences, Inc. | 4,977,089 | 0 (0.00%) | 24.31% | $117 M | Nov 6, 2026 |
| 2 | Farallon Capital Management, L.L.C. | 1,604,590 | 0 (0.00%) | 7.84% | $38 M | Nov 16, 2026 |
| 3 | Paradigm Biocapital Advisors LP | 1,553,748 | 0 (0.00%) | 7.59% | $36 M | Nov 16, 2026 |
| 4 | BlackRock, Inc. | 1,488,018 | +721,199 (+94.05%) | 7.27% | $35 M | Nov 13, 2026 |
| 5 | Ra Capital Management, L.P. | 1,020,410 | 0 (0.00%) | 4.98% | $24 M | Nov 16, 2026 |
| 6 | Parkman Healthcare Partners LLC | 796,256 | +75,075 (+10.41%) | 3.89% | $19 M | Nov 16, 2026 |
| 7 | Vanguard Capital Management LLC | 602,932 | +43,990 (+7.87%) | 2.94% | $14 M | Nov 13, 2026 |
| 8 | State Street Corp | 559,590 | +387,659 (+225.47%) | 2.73% | $13 M | Nov 12, 2026 |
| 9 | Millennium Management LLC | 490,137 | +191,330 (+64.03%) | 2.39% | $12 M | Nov 16, 2026 |
| 10 | Commodore Capital LP | 461,922 | -953,078 (-67.36%) | 2.26% | $11 M | Nov 16, 2026 |
| 11 | Seven Fleet Capital Management LP | 417,441 | -15,706 (-3.63%) | 2.04% | $10 M | Nov 16, 2026 |
| 12 | Citadel Advisors LLC | 379,812 | +283,905 (+296.02%) | 1.85% | $9 M | Nov 16, 2026 |
| 13 | Point72 Asset Management, L.P. | 362,728 | -97,865 (-21.25%) | 1.77% | $9 M | Nov 16, 2026 |
| 14 | Geode Capital Management, LLC | 361,152 | +80,728 (+28.79%) | 1.76% | $8 M | Nov 6, 2026 |
| 15 | Ameriprise Financial Inc | 288,397 | +58,397 (+25.39%) | 1.41% | $7 M | Nov 16, 2026 |
| 16 | HRT Financial LP | 230,777 | New | 1.13% | $5 M | Nov 13, 2026 |
| 17 | Schonfeld Strategic Advisors LLC | 228,002 | -14,151 (-5.84%) | 1.11% | $5 M | Nov 16, 2026 |
| 18 | DV Equities, LLC | 226,415 | 0 (0.00%) | 1.11% | $5 M | Nov 16, 2026 |
| 19 | Squadron Capital Management LLC | 225,000 | +65,000 (+40.62%) | 1.10% | $5 M | Nov 16, 2026 |
| 20 | Goldman Sachs Group Inc | 191,747 | +53,914 (+39.12%) | 0.94% | $5 M | Nov 16, 2026 |
| 21 | B Group, Inc. | 175,706 | 0 (0.00%) | 0.86% | $4 M | Nov 16, 2026 |
| 22 | Janus Henderson Group Ltd. | 164,142 | — | 0.80% | $4 M | Nov 16, 2026 |
| 23 | Woodline Partners LP | 150,780 | 0 (0.00%) | 0.74% | $4 M | Nov 16, 2026 |
| 24 | Northern Trust Corp | 142,299 | +19,270 (+15.66%) | 0.69% | $3 M | Nov 16, 2026 |
| 25 | Driehaus Capital Management LLC | 128,307 | -21,693 (-14.46%) | 0.63% | $3 M | Nov 16, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Vanguard Portfolio Management LLC | 124,931 | +33,778 (+37.06%) | 0.61% | $3 M | Nov 13, 2026 |
| 27 | Qube Research & Technologies Ltd | 114,422 | +62,934 (+122.23%) | 0.56% | $3 M | Nov 13, 2026 |
| 28 | Franklin Templeton Inc | 113,200 | 0 (0.00%) | 0.55% | $3 M | Nov 12, 2026 |
| 29 | Renaissance Technologies LLC | 112,017 | +72,576 (+184.01%) | 0.55% | $3 M | Nov 12, 2026 |
| 30 | Vanguard Fiduciary Trust Co | 95,578 | +21,608 (+29.21%) | 0.47% | $2 M | Nov 13, 2026 |
| 31 | HighVista Strategies LLC | 93,224 | +19,819 (+27.00%) | 0.46% | $2 M | Nov 13, 2026 |
| 32 | Nuveen, LLC | 85,906 | +69,031 (+409.07%) | 0.42% | $2 M | Nov 10, 2026 |
| 33 | Squarepoint Ops LLC | 73,732 | +39,518 (+115.50%) | 0.36% | $2 M | Nov 9, 2026 |
| 34 | Morgan Stanley | 69,111 | +23,892 (+52.84%) | 0.34% | $2 M | Nov 13, 2026 |
| 35 | Los Angeles Capital Management LLC | 60,342 | New | 0.29% | $1 M | Nov 12, 2026 |
| 36 | Trexquant Investment LP | 57,147 | +11,486 (+25.15%) | 0.28% | $1 M | Nov 16, 2026 |
| 37 | Monimus Capital Management, LP | 47,580 | 0 (0.00%) | 0.23% | $1 M | Nov 16, 2026 |
| 38 | Jump Financial, LLC | 45,898 | New | 0.22% | $1 M | Nov 13, 2026 |
| 39 | Charles Schwab Investment Management Inc | 39,202 | +10,074 (+34.59%) | 0.19% | $1 M | Nov 16, 2026 |
| 40 | Arrowstreet Capital, Limited Partnership | 38,857 | New | 0.19% | $1 M | Nov 13, 2026 |
| 41 | Gsa Capital Partners LLP | 38,286 | -4,645 (-10.82%) | 0.19% | $1 M | Nov 16, 2026 |
| 42 | BNP Paribas Financial Markets | 34,995 | +10,792 (+44.59%) | 0.17% | $1 M | Nov 12, 2026 |
| 43 | Man Group plc | 34,713 | New | 0.17% | $1 M | Nov 16, 2026 |
| 44 | Wellington Management Group LLP | 34,685 | New | 0.17% | $1 M | Nov 16, 2026 |
| 45 | UBS Group AG | 33,125 | -8,681 (-20.76%) | 0.16% | $1 M | Nov 10, 2026 |
| 46 | Bank of New York Mellon Corp | 32,972 | +8,957 (+37.30%) | 0.16% | $1 M | Nov 5, 2026 |
| 47 | Connor, Clark & Lunn Investment Management Ltd. | 32,652 | +8,887 (+37.40%) | 0.16% | $1 M | Nov 10, 2026 |
| 48 | XTX Topco Ltd | 30,777 | -12,141 (-28.29%) | 0.15% | $1 M | Nov 16, 2026 |
| 49 | Engineers Gate Manager LP | 30,650 | +12,884 (+72.52%) | 0.15% | $1 M | Nov 16, 2026 |
| 50 | FMR LLC | 28,560 | +28,382 (+15944.94%) | 0.14% | $1 M | Nov 10, 2026 |
| 51 | HSBC Holdings PLC | 28,405 | +11,470 (+67.73%) | 0.14% | $1 M | Nov 16, 2026 |
| 52 | Massachusetts Financial Services Co /ma/ | 28,126 | New | 0.14% | $1 M | Nov 12, 2026 |
| 53 | Quadrature Capital Ltd | 25,413 | New | 0.12% | $1 M | Nov 13, 2026 |
| 54 | Bank Of America Corp /de/ | 25,303 | +15,736 (+164.48%) | 0.12% | $1 M | Nov 16, 2026 |
| 55 | ADAR1 Capital Management, LLC | 21,447 | +1,000 (+4.89%) | 0.10% | $1 M | Nov 16, 2026 |
| 56 | Jane Street Group, LLC | 21,201 | New | 0.10% | $0 M | Nov 12, 2026 |
| 57 | Ally Bridge Group (NY) LLC | 18,298 | -121,702 (-86.93%) | 0.09% | $0 M | Nov 16, 2026 |
| 58 | American Century Companies Inc | 17,869 | +4,630 (+34.97%) | 0.09% | $0 M | Nov 12, 2026 |
| 59 | Barclays PLC | 16,838 | +10,705 (+174.55%) | 0.08% | $0 M | Nov 6, 2026 |
| 60 | Eversept Partners, LP | 16,510 | 0 (0.00%) | 0.08% | $0 M | Nov 16, 2026 |
| 61 | Palumbo Wealth Management LLC | 15,900 | -3,965 (-19.96%) | 0.08% | $0 M | Nov 13, 2026 |
| 62 | Invesco Ltd. | 15,266 | +3,402 (+28.67%) | 0.07% | $0 M | Nov 12, 2026 |
| 63 | Osaic Holdings, Inc. | 14,709 | +14,609 (+14609.00%) | 0.07% | $0 M | Nov 12, 2026 |
| 64 | EntryPoint Capital, LLC | 14,702 | +6,417 (+77.45%) | 0.07% | $0 M | Nov 13, 2026 |
| 65 | Virtus Investment Advisers, LLC | 13,821 | -430 (-3.02%) | 0.07% | $0 M | Nov 12, 2026 |
| 66 | Rafferty Asset Management, LLC | 13,098 | New | 0.06% | $0 M | Nov 13, 2026 |
| 67 | Rhumbline Advisers | 12,981 | +1,391 (+12.00%) | 0.06% | $0 M | Nov 10, 2026 |
| 68 | Algert Global LLC | 11,570 | New | 0.06% | $0 M | Nov 17, 2026 |
| 69 | Deutsche Bank AG\ | 11,243 | +1,628 (+16.93%) | 0.05% | $0 M | Nov 6, 2026 |
| 70 | Price T Rowe Associates Inc /MD/ | 11,022 | +2,819 (+34.37%) | 0.05% | $0 M | Nov 16, 2026 |
| 71 | Susquehanna International Group, LLP | 10,615 | New | 0.05% | $0 M | Nov 16, 2026 |
| 72 | Dakota Wealth Management | 10,000 | New | 0.05% | $0 M | Nov 12, 2026 |
| 73 | State Of Wisconsin Investment Board | 9,898 | New | 0.05% | $0 M | Nov 16, 2026 |
| 74 | Two Sigma Investments, LP | 9,089 | -8,769 (-49.10%) | 0.04% | $0 M | Nov 16, 2026 |
| 75 | MetLife Investment Management, LLC | 7,717 | +1,832 (+31.13%) | 0.04% | $0 M | Nov 16, 2026 |
| 76 | Jpmorgan Chase & Co | 7,415 | -38,970 (-84.01%) | 0.04% | $0 M | Nov 12, 2026 |
| 77 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 7,410 | +2,891 (+63.97%) | 0.04% | $0 M | Nov 16, 2026 |
| 78 | Persistent Asset Partners Ltd | 6,132 | -810 (-11.67%) | 0.03% | $0 M | Nov 13, 2026 |
| 79 | Vanguard Global Advisers, LLC | 5,686 | +1,071 (+23.21%) | 0.03% | $0 M | Nov 13, 2026 |
| 80 | Citigroup Inc | 5,578 | +1,024 (+22.49%) | 0.03% | $0 M | Nov 4, 2026 |
| 81 | Royal Bank Of Canada | 4,376 | +3,936 (+894.55%) | 0.02% | $0 M | Nov 16, 2026 |
| 82 | New York State Common Retirement Fund | 4,200 | 0 (0.00%) | 0.02% | $0 M | Nov 17, 2026 |
| 83 | Police & Firemen's Retirement System of New Jersey | 3,763 | +856 (+29.45%) | 0.02% | $0 M | Nov 9, 2026 |
| 84 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 2,784 | New | 0.01% | $0 M | Nov 16, 2026 |
| 85 | Wells Fargo & Company/mn | 2,599 | -5,654 (-68.51%) | 0.01% | $0 M | Nov 16, 2026 |
| 86 | Legal & General Group Plc | 1,226 | +268 (+27.97%) | 0.01% | $0 M | Nov 16, 2026 |
| 87 | Ameritas Investment Partners, Inc. | 1,192 | +297 (+33.18%) | 0.01% | $0 M | Nov 13, 2026 |
| 88 | State of Alaska, Department of Revenue | 989 | New | 0.00% | $0 M | Oct 15, 2026 |
| 89 | Tower Research Capital LLC (TRC) | 970 | +440 (+83.02%) | 0.00% | $0 M | Nov 16, 2026 |
| 90 | Russell Investments Group, Ltd. | 788 | 0 (0.00%) | 0.00% | $0 M | Nov 6, 2026 |
| 91 | Simplex Trading, LLC | 480 | New | 0.00% | $0 M | Nov 4, 2026 |
| 92 | Sterling Capital Management LLC | 260 | +61 (+30.65%) | 0.00% | $0 M | Oct 22, 2026 |
| 93 | Accent Capital Management, LLC | 212 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 94 | California State Teachers Retirement System | 136 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 95 | Global Retirement Partners, LLC | 67 | New | 0.00% | $0 M | Nov 10, 2026 |
| 96 | EverSource Wealth Advisors, LLC | 59 | +4 (+7.27%) | 0.00% | $0 M | Nov 4, 2026 |
| 97 | Parkside Financial Bank & Trust | 54 | New | 0.00% | $0 M | Oct 27, 2026 |
| 98 | BFC Planning, Inc. | 41 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 99 | GAMMA Investing LLC | 20 | New | 0.00% | $0 M | Oct 8, 2026 |
| 100 | Allworth Financial LP | 19 | +9 (+90.00%) | 0.00% | $0 M | Nov 17, 2026 |
Mutual funds holding Assembly Biosciences, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 413,284 | $11 M | 2.0% | <0.01% | +19% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 244,994 | $7 M | 1.2% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 133,292 | $4 M | 0.65% | <0.01% | +2.5% | Jun 30, 2026 |
| 🇺🇸 abrdn Healthcare Investorsabrdn Inc. | 129,708 | $4 M | 0.63% | 0.26% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 107,386 | $3 M | 0.52% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 89,271 | $2 M | 0.44% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 abrdn Life Sciences Investorsabrdn Inc. | 77,339 | $2 M | 0.38% | 0.31% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 58,396 | $2 M | 0.29% | <0.01% | −1.2% | May 31, 2026 |
| 🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc. | 40,982 | $1 M | 0.20% | 0.09% | new | Jul 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 33,135 | $1 M | 0.16% | 0.06% | +43% | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 23,781 | $1 M | 0.12% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 21,252 | $1 M | 0.10% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Small Cap Value FundNorthern Trust Investments, Inc. | 20,728 | $1 M | 0.10% | 0.08% | new | Jun 30, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 18,425 | $1 M | 0.09% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 16,917 | $0 M | 0.08% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc. | 88,900 | $0 M | 0.09% | 0.04% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 13,750 | $0 M | 0.07% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 13,206 | $0 M | 0.06% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 10,575 | $0 M | 0.05% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 9,732 | $0 M | 0.05% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 9,650 | $0 M | 0.05% | <0.01% | +58% | May 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 7,300 | $0 M | 0.04% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 6,351 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 6,716 | $0 M | 0.03% | <0.01% | +67% | Jul 31, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 6,704 | $0 M | 0.03% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 6,073 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 5,773 | $0 M | 0.03% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 5,076 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 4,810 | $0 M | 0.02% | <0.01% | +38% | Jun 30, 2026 |
| 🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc. | 4,808 | $0 M | 0.02% | 0.03% | −3.2% | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 4,707 | $0 M | 0.02% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 4,201 | $0 M | 0.02% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 4,019 | $0 M | 0.02% | <0.01% | +3.0% | Jul 31, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 3,547 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 3,337 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 2,793 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 2,237 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 2,230 | $0 M | 0.01% | 0.03% | +34% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 2,164 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 2,020 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 2,020 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 1,791 | $0 M | <0.01% | 0.01% | +5.8% | Jul 31, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 1,547 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 1,665 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 1,512 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 1,504 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 1,322 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 1,441 | $0 M | <0.01% | <0.01% | +20% | Jul 31, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity FundAmerican Century ETF Trust | 1,166 | $0 M | <0.01% | 0.02% | no change | May 31, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 1,176 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 1,100 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 1,154 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 895 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 817 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 788 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 861 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 750 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 731 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 735 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 490 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC | 420 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 345 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC | 276 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 277 | $0 M | <0.01% | <0.01% | −5.5% | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 249 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 61 | $0 M | <0.01% | <0.01% | +5.2% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 66 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Assembly Biosciences, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Jeanette M. BjorkquistPFO and PAO | Sell | -718 | $19.61 | $14 K | 17,682 | Form 4 |
| filed | Anuj GaggarChief Medical Officer | Sell | -2,564 | $19.61 | $50 K | 53,829 | Form 4 |
| filed | Nicole S. WhiteChief Manufacturing Officer | Sell | -2,564 | $19.61 | — | 59,286 | Form 4 |
| filed | Jason A. OkazakiCEO and President, Director | Sell | -6,133 | $19.61 | $120 K | 195,601 | Form 4 |
| filed | Jason A. OkazakiCEO and President, Director | Sell | -69 | $20.35 | $1 K | 195,532 | Form 4 |
| filed | Anuj GaggarChief Medical Officer | Sell | -29 | $20.35 | $590 | 53,800 | Form 4 |
| filed | Jeanette M. BjorkquistPFO and PAO | Sell | -9 | $20.35 | $183 | 17,673 | Form 4 |
| filed | Nicole S. WhiteChief Manufacturing Officer | Sell | -29 | $20.35 | — | 59,257 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Assembly Biosciences, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-12 reverse split
Fails to deliver
- : 2,907 shares at $21.19
- : 2,727 shares at $34.07
- : 4,381 shares at $32.13
- : 283 shares at $32.95
- : 51 shares at $26.44
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Assembly Biosciences, Inc. scorecard#
Passes 6 of the 16 checks that could be worked out: strongest in growth (2 of 3), weakest in profitability (1 of 4). Fiscal year 2025; market cap of Oct 21, 2026.
Valuation2 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median2.1×Price to book 2.1× against Biotechnology's median of 2.9×.
- ✓Price to sales below its peers' median6.5×Price to sales 6.5× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-9.5%Free cash flow is -9.5% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth2 of 3
- ✓Revenue grew in the newest year153.5%Revenue up 153.5% in fiscal 2025.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.55 vs -6.69Diluted EPS -0.55 in fiscal 2025 against -6.69 the year before (report's currency).
- ✓Net income higher than five years earlier-$6 M-$6 M in fiscal 2025 against -$62 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability1 of 4
- ✗Profitable in the newest year-$6 MNet income -$6 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✓Operating margin above its peers' median-16.8%-16.8% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-5.1%-5.1% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities5.2×Current ratio 5.22 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone1.68Z-score 1.68 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year86.7%Diluted shares up 86.7% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Assembly Biosciences, Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -16.8% | -60.5% | |
| Net margin | -8.5% | -68.9% | |
| Return on equity | -5.1% | -61.0% | |
| Revenue growth | 153.5% | 15.8% | |
| Free cash flow margin | -56.9% | -61.5% |
3of 7on the Piotroski tests of financial strength
- Net loss of $6 million, the 17th loss-making year in a row.
- Free cash flow was negative: -$41 million.
- The share count rose 86.7% in the year.
Assembly Biosciences, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 72+154%100% | 29+298%100% | 7.2—100% | 0−100%— | 6.3−92.1%100% | 79+396%100% | 16+7.8%100% | 15+64.1%100% | 9.0—100% | 0—— | |
| Research and development | 65+15.9%89.6% | 56+14.4%196% | 49−30.1%683% | 70+2.1%— | 69−35.9%1096% | 107+24.6%135% | 86+17.9%537% | 73+64.5%491% | 44r44+33.6%490% | 33r33—— | |
| General and administrative | 20+8.9%27.1% | 18−21.4%63.1% | 23−5.1%320% | 24−16.1%— | 29−22.3%460% | 37+12.6%46.8% | 33−5.4%206% | 35+104%235% | 17r17+39.7%189% | 12r12—— | |
| Operating expenses | 84+14.2%117% | 74+3.0%259% | 72−23.7%1002% | 94−32.3%— | 139−3.4%2222% | 144+21.2%182% | 119+10.4%743% | 108+75.6%726% | 61—679% | — | |
| Operating income | −12—−16.8% | −45—−159% | −65—−902% | −94—— | −133—−2122% | −65—−81.9% | −103—−643% | −93—−626% | −52r−52—−579% | −45r−45—— | |
| Other non-operating income (expense) | 6.0+7.6%8.3% | 5.6+61.5%19.5% | 3.5+238%48.2% | 1.0+238%— | 0.3−88.5%4.8% | 2.6−39.0%3.3% | 4.3+39.6%27.0% | 3.1+738%20.8% | 0.4r0.4−7.8%4.1% | 0.4r0.4—— | |
| Income before tax | −6.1—−8.5% | −40—−140% | −61—−854% | −93—— | −132—−2117% | −62—−78.6% | −98—−616% | −90—−606% | −52r−52—−575% | −45r−45—— | |
| Income tax | 0−100%0.0% | 0.3+900%1.2% | 0.0—0.5% | 0—— | −2.5—−40.5% | 0—0.0% | −0.8−170%−4.8% | 1.1—7.4% | −9.1r−9.1—−100% | −0.6r−0.6—— | |
| Net income including minority interests | −6.1—−8.5% | −40—−141% | −61—−855% | −93—— | −130—−2076% | −62—−78.6% | −98—−612% | −91—−613% | −43—−475% | — | |
| Net income attributable to shareholders | −6.1—−8.5% | −40—−141% | −61—−855% | −93—— | −130—−2076% | −62—−78.6% | −98—−612% | −91—−613% | −43r−43—−475% | −44r−44—— | |
| Earnings per share, basic | -0.55—— | -6.69—— | -13.38—— | -23.08r-1.92—— | -3.00—— | -1.75—— | -3.72—— | -3.98—— | -2.41—— | -2.57—— | |
| Earnings per share, diluted | -0.55—— | -6.69—— | -13.38—— | -23.08r-1.92—— | -3.00—— | -1.75—— | -3.72—— | -3.98—— | -2.41—— | -2.57—— | |
| Shares, weighted average (basic) | 11+86.7%— | 6.0+31.2%— | 4.6+13.5%— | 4.0r48−90.7%— | 43—— | — | — | — | — | — | |
| Shares, weighted average (diluted) | 11+86.7%— | 6.0+31.2%— | 4.6+13.5%— | 4.0r48−90.7%— | 43+22.2%— | 35+34.9%— | 26+15.2%— | 23+28.5%— | 18+3.0%— | 17—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 58+52.4%22.7% | 38+93.3%32.2% | 20−62.1%14.5% | 52+14.9%51.5% | 46−23.2%23.9% | 59+27.2%21.0% | 47+12.7%13.7% | 41−49.4%15.5% | 82r82+187%48.5% | 29r29—29.1% | |
| Short-term investments | 190+157%73.6% | 74−33.2%61.9% | 110+182%80.7% | 39−61.2%38.5% | 101−35.7%52.9% | 157−30.9%55.4% | 227+28.7%66.9% | 177+366%65.9% | 38r38+55.5%22.4% | 24—24.9% | |
| Receivables | 1.0—0.4% | 0−100%0.0% | 0.0−95.4%0.0% | 0.9+181%0.9% | 0.3−72.7%0.2% | 1.2−63.5%0.4% | 3.4+38.8%1.0% | 2.4+6.9%0.9% | 2.3r2.3—1.3% | 0—0.0% | |
| Other current assets | 5.5+59.7%2.1% | 3.4−2.1%2.9% | 3.5−20.8%2.6% | 4.4−39.1%4.3% | 7.2+5.7%3.8% | 6.9+27.7%2.4% | 5.4+169%1.6% | 2.0+122%0.7% | 0.9r0.9+46.9%0.5% | 0.6—0.6% | |
| Current assets | 255+120%98.8% | 116−13.7%96.9% | 134+38.0%97.8% | 97−37.1%95.3% | 154−31.3%80.7% | 224−20.6%79.3% | 283+27.1%83.2% | 223+80.7%83.0% | 123r123+130%72.7% | 54—54.6% | |
| Property, plant and equipment | 0.2−22.2%0.1% | 0.3−26.2%0.2% | 0.4−48.2%0.3% | 0.7−34.8%0.7% | 1.1−28.8%0.6% | 1.6−12.6%0.6% | 1.8+229%0.5% | 0.6−35.2%0.2% | 0.9r0.9+301%0.5% | 0.2—0.2% | |
| Right-of-use (leased) assets | 2.5−18.3%1.0% | 3.1+31.2%2.6% | 2.3−26.8%1.7% | 3.2−47.1%3.1% | 6.0−33.8%3.2% | 9.1−23.7%3.2% | 12—3.5% | 0—0.0% | — | — | |
| Goodwill | — | — | — | — | — | 130.0%4.5% | 130.0%3.7% | 130.0%4.7% | 13r13−0.0%7.5% | 13—12.9% | |
| Other intangible assets | — | — | — | — | — | — | — | — | 290.0%17.1% | 29—29.6% | |
| Non-current assets | — | — | — | — | — | — | — | 46−1.4%17.0% | 46r46+3.7%27.3% | 45—45.4% | |
| Total assets | 258+116%100% | 119−12.9%100% | 137+34.4%100% | 102−46.7%100% | 191−32.5%100% | 283−16.7%100% | 340+26.8%100% | 268+58.3%100% | 169r169+72.6%100% | 98—100% | |
| Accounts payable | 1.2+100%0.5% | 0.6+26.9%0.5% | 0.5−81.5%0.3% | 2.5−6.2%2.4% | 2.7−42.2%1.4% | 4.6+166%1.6% | 1.7−53.1%0.5% | 3.7—1.4% | — | — | |
| Current liabilities | 49+2.0%18.9% | 48+21.9%40.1% | 39+141%28.7% | 16+1.4%16.0% | 16−34.2%8.4% | 24−0.0%8.6% | 24+32.3%7.2% | 18+36.9%6.9% | 13r13+89.5%8.0% | 7.1—7.3% | |
| Lease liabilities (non-current) | 2.1−21.7%0.8% | 2.6+134%2.2% | 1.1+1011%0.8% | 0.1−97.0%0.1% | 3.3−50.6%1.7% | 6.7−26.0%2.4% | 9.1—2.7% | 0—0.0% | — | — | |
| Non-current liabilities | — | — | — | — | — | — | — | 39−8.8%14.5% | 43r43+284%25.2% | 11—11.3% | |
| Total liabilities | 51−40.8%19.7% | 86−10.4%72.0% | 96+400%70.0% | 19−13.6%18.8% | 22−48.1%11.6% | 43−36.0%15.1% | 67+16.2%19.6% | 57+2.2%21.4% | 56r56+208%33.2% | 18—18.6% | |
| Retained earnings | −832—−323% | −826—−693% | −786—−574% | −725—−712% | −631—−330% | −502—−177% | −439—−129% | −342—−128% | −251r−251—−148% | −208—−212% | |
| Shareholders' equity | 207+520%80.3% | 33−18.8%28.0% | 41−50.3%30.0% | 83−51.1%81.2% | 169−29.8%88.4% | 241−11.9%84.9% | 273+29.7%80.4% | 211+86.2%78.6% | 113r113+41.6%66.8% | 80r80—81.4% | |
| Total liabilities and equity | 258+116%100% | 119−12.9%100% | 137+34.4%100% | 102−46.7%100% | 191−32.5%100% | 283−16.7%100% | 340+26.8%100% | 268+58.3%100% | 169r169+72.6%100% | 98—100% | |
| Shares outstanding | 16+113%— | 7.5+36.0%— | 5.5+34.6%— | 4.1r49−91.5%— | 48+41.4%— | 34+4.5%— | 33+27.7%— | 25+26.6%— | 20+16.8%— | 17—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.10.0%0.2% | 0.1−71.3%0.5% | 0.5−9.6%6.3% | 0.5+6.9%— | 0.5−32.6%7.5% | 0.7+39.9%0.9% | 0.5−23.2%3.1% | 0.6+194%4.3% | 0.2—2.4% | — | |
| Share-based compensation | 4.7+49.9%6.5% | 3.1−39.1%10.9% | 5.1−22.4%71.5% | 6.6+25.9%— | 5.2−76.0%83.7% | 22+6.3%27.6% | 21−27.8%129% | 28+231%192% | 8.6r8.6+71.2%95.4% | 5.0r5.0—— | |
| Cash from operating activities | −41—−56.8% | −51−325%−179% | 23—318% | −84—— | −93—−1493% | −63—−79.6% | −84—−527% | −65−3592%−439% | 1.9r1.9—20.6% | −35r−35—— | |
| Capital expenditure | −0.1—−0.1% | −0.0—−0.1% | −0.3—−3.6% | −0.1—— | −3.1—−49.5% | −0.5—−0.6% | −1.6—−9.7% | −0.3—−2.3% | −0.9r−0.9—−9.6% | −0.1r−0.1—— | |
| Acquisitions, net of cash acquired | — | — | — | — | — | — | — | — | — | 0—— | |
| Cash from investing activities | −113−382%−157% | 40—141% | −69−176%−965% | 91+242%— | 27−61.0%424% | 68—86.1% | −50—−315% | −135—−915% | −16r−16−143%−173% | 36r36—— | |
| Shares issued | 1.9−5.3%2.7% | 2.0−55.3%7.1% | 4.5+1299%63.5% | 0.3−99.4%— | 53+869%844% | 5.5−96.0%6.9% | 135−13.4%844% | 155+140%1050% | 65—719% | — | |
| Cash from financing activities | 175+493%242% | 29+113%103% | 14+2150%193% | 0.6−98.8%— | 53+598%848% | 7.6−94.6%9.6% | 140−12.6%875% | 160+138%1079% | 67r67+43848%746% | 0.2r0.2—— | |
| Change in cash | 20+8.7%27.8% | 19—64.9% | −33−580%−455% | 6.8—— | −14−209%−221% | 13+142%16.1% | 5.3—33.0% | −41−176%−274% | 53r53+3544%593% | 1.5r1.5—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | 3.0−72.6%100% | 13+38.9%100% | 8.2−12.8%100% | — | 11+57.6%100% | 9.6+12.8%100% | 9.4+62.8%100% | 7.4*+2.7%100% | 6.8—100% | 8.5—100% | 5.8—100% | 7.2*—100% | |
| Research and development | 67+8.8%— | 20+22.0%685% | 15−7.5%112% | 15+0.3%181% | 17*+20.8%— | 17+22.7%154% | 16−0.8%168% | 15+25.0%158% | 14*+29.7%194% | 14—197% | 16—191% | 12—205% | 11*—154% | |
| General and administrative | 21+11.9%— | 6.1+20.7%208% | 4.8+4.5%35.9% | 4.7+3.9%57.0% | 5.4*+17.6%— | 5.1+18.6%47.1% | 4.6+2.6%47.7% | 4.5−2.7%47.9% | 4.6*−47.1%62.6% | 4.3—62.6% | 4.5—52.5% | 4.6—80.1% | 8.7*—122% | |
| Operating expenses | 88+9.6%— | 26+21.7%892% | 20−4.8%147% | 20+1.2%238% | 23*+20.0%— | 22+21.7%201% | 21−0.1%215% | 19+17.2%206% | 19*−4.2%257% | 18—260% | 21—243% | 17—285% | 20*—275% | |
| Operating income | −21—— | −23—−792% | −6.3—−47.4% | −11—−138% | 20*—— | −11—−101% | −11—−115% | −9.9—−106% | −12*—−157% | −11—−160% | −12—−143% | −11—−185% | −13*—−175% | |
| Other non-operating income (expense) | 10+112%— | 3.2+87.3%107% | 2.5+178%18.6% | 2.3+104%27.9% | 2.3*+104%— | 1.7+25.6%15.6% | 0.9−38.6%9.3% | 1.1−32.0%11.9% | 1.1*−30.9%15.2% | 1.3—19.6% | 1.5—17.1% | 1.7—28.6% | 1.6*—22.6% | |
| Income before tax | — | — | — | — | 22*—— | −9.2—−85.2% | −10—−106% | — | −10*—−142% | −9.6—−140% | −11—−126% | — | −11*—−153% | |
| Income tax | — | — | — | — | 0*—— | 0—0.0% | 0−100%0.0% | — | −0.1*−330%−1.0% | 0—0.0% | 0.4—4.8% | — | 0.0*—0.5% | |
| Net income including minority interests | −11—— | −20*—−685% | −3.9*—−28.8% | −9.1—−111% | 22*—— | −9.2*—−85.2% | −10*—−106% | −8.8—−93.6% | −10*—−140% | −9.6*—−140% | −11*—−131% | −9.1—−157% | −11*—−153% | |
| Net income attributable to shareholders | −11—— | −20—−685% | −3.9—−28.8% | −9.1—−111% | 22*—— | −9.2—−85.2% | −10—−106% | −8.8—−93.6% | −10*—−140% | −9.6—−140% | −11—−131% | −9.1—−157% | −11*—−153% | |
| Earnings per share, basic | — | -0.93—— | -0.20—— | -0.54—— | — | -0.72—— | -1.33—— | -1.17—— | — | -1.51—— | -1.98—— | -1.66—— | — | |
| Earnings per share, diluted | — | -0.93—— | -0.20—— | -0.54—— | — | -0.72—— | -1.33—— | -1.17—— | — | -1.51—— | -1.98—— | -1.66—— | — | |
| Shares, weighted average (basic) | 22+71.7%— | 22+71.7%— | 19+146%— | 17+125%— | — | 13+99.7%— | 7.7+35.7%— | 7.5+36.9%— | — | 6.4—— | 5.6—— | 5.5—— | — | |
| Shares, weighted average (diluted) | 22+71.7%— | 22+71.7%— | 19+146%— | 17+125%— | — | 13+99.7%— | 7.7+35.7%— | 7.5+36.9%— | — | 6.4—— | 5.6—— | 5.5—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 29—8.9% | 29+29.0%8.9% | 32+34.5%9.8% | 31+32.9%13.2% | 58+52.4%22.7% | 23−20.8%9.4% | 24+25.0%29.7% | 23+24.9%23.6% | 38+93.3%32.2% | 28—28.4% | 19—16.7% | 19—15.6% | 20—14.5% | |
| Short-term investments | 285—87.7% | 285+35.8%87.7% | 288+465%87.1% | 195+189%83.0% | 190+157%73.6% | 210+216%87.5% | 51−43.4%63.1% | 68−28.2%68.3% | 74−33.2%61.9% | 67—66.3% | 90—78.1% | 94—78.6% | 110—80.7% | |
| Receivables | 0.6—0.2% | 0.6−36.2%0.2% | 0.8—0.2% | 0.5—0.2% | 1.0—0.4% | 0.9—0.4% | — | — | 0−100%0.0% | 0—0.0% | 0—0.0% | 0.0—0.0% | 0.0—0.0% | |
| Other current assets | 6.3—1.9% | 6.3+88.9%1.9% | 6.8+173%2.1% | 5.6+23.6%2.4% | 5.5+59.7%2.1% | 3.3+2.6%1.4% | 2.5−33.0%3.1% | 4.5+8.4%4.5% | 3.4−2.1%2.9% | 3.3—3.3% | 3.7—3.2% | 4.1—3.5% | 3.5—2.6% | |
| Current assets | 321—98.7% | 321+35.6%98.7% | 328+323%99.1% | 233+144%98.8% | 255+120%98.8% | 237+141%98.7% | 77−31.4%95.9% | 96−18.5%96.5% | 116−13.7%96.9% | 98—98.0% | 113—97.9% | 117—97.7% | 134—97.8% | |
| Property, plant and equipment | 0.3—0.1% | 0.3+27.1%0.1% | 0.3+43.8%0.1% | 0.2−14.7%0.1% | 0.2−22.2%0.1% | 0.2−27.5%0.1% | 0.2−37.2%0.3% | 0.3−31.6%0.3% | 0.3−26.2%0.2% | 0.3—0.3% | 0.3—0.3% | 0.4—0.3% | 0.4—0.3% | |
| Right-of-use (leased) assets | 2.1—0.6% | 2.1−21.3%0.6% | 2.2−19.9%0.7% | 2.4−19.1%1.0% | 2.5−18.3%1.0% | 2.6+86.1%1.1% | 2.8+60.7%3.4% | 2.9+43.8%3.0% | 3.1+31.2%2.6% | 1.4—1.4% | 1.7—1.5% | 2.0—1.7% | 2.3—1.7% | |
| Total assets | 325—100% | 325+35.5%100% | 331+310%100% | 236+138%100% | 258+116%100% | 240+139%100% | 81−30.0%100% | 99−17.4%100% | 119−12.9%100% | 100—100% | 115—100% | 120—100% | 137—100% | |
| Accounts payable | 3.2—1.0% | 3.2+89.1%1.0% | 1.2+58.8%0.4% | 1.1+29.0%0.5% | 1.2+100%0.5% | 1.7+26.1%0.7% | 0.7−7.2%0.9% | 0.9+20.4%0.9% | 0.6+26.9%0.5% | 1.3—1.3% | 0.8—0.7% | 0.7—0.6% | 0.5—0.3% | |
| Current liabilities | 25—7.7% | 25−53.3%7.7% | 23−50.4%7.1% | 35−24.9%14.9% | 49+2.0%18.9% | 53+28.2%22.2% | 47+14.6%58.5% | 47+20.3%47.1% | 48+21.9%40.1% | 42—41.5% | 41—35.8% | 39—32.3% | 39—28.7% | |
| Lease liabilities (non-current) | 1.6—0.5% | 1.6−28.8%0.5% | 1.7−26.1%0.5% | 1.9−23.7%0.8% | 2.1−21.7%0.8% | 2.2+1853%0.9% | 2.4+421%2.9% | 2.5+215%2.5% | 2.6+134%2.2% | 0.1—0.1% | 0.5—0.4% | 0.8—0.7% | 1.1—0.8% | |
| Total liabilities | 26—8.1% | 26−53.8%8.1% | 25−59.8%7.6% | 37−48.7%15.7% | 51−40.8%19.7% | 57−22.8%23.9% | 63−22.3%77.6% | 72−17.6%72.6% | 86−10.4%72.0% | 74—74.1% | 81—69.9% | 87—72.8% | 96—70.0% | |
| Retained earnings | −865—−266% | −865—−266% | −845—−255% | −841—−357% | −832—−323% | −854—−356% | −845—−1046% | −835—−843% | −826—−693% | −816—−813% | −806—−699% | −795—−663% | −786—−574% | |
| Shareholders' equity | 299—91.9% | 299+63.5%91.9% | 306+1589%92.4% | 199+632%84.3% | 207+520%80.3% | 183+603%76.1% | 18−47.8%22.4% | 27−16.8%27.4% | 33−18.8%28.0% | 26—25.9% | 35—30.1% | 33—27.2% | 41—30.0% | |
| Total liabilities and equity | 325—100% | 325+35.5%100% | 331+310%100% | 236+138%100% | 258+116%100% | 240+139%100% | 81−30.0%100% | 99−17.4%100% | 119−12.9%100% | 100—100% | 115—100% | 120—100% | 137—100% | |
| Shares outstanding | 20—— | 20+28.8%— | 20+159%— | 16+109%— | 16+113%— | 16+149%— | 7.7+20.9%— | 7.6+39.0%— | 7.5+36.0%— | 6.4—— | 6.3—— | 5.5—— | 5.5—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.1−20.9%— | 0.0*−25.0%0.8% | 0.0*−37.5%0.1% | 0.0−21.2%0.3% | 0.0*0.0%— | 0.0*−3.0%0.3% | 0.0*0.0%0.3% | 0.0+3.1%0.4% | 0.0*−61.9%0.4% | 0.0*—0.5% | 0.0*—0.4% | 0.0—0.6% | 0.1*—1.2% | |
| Share-based compensation | 8.3+110%— | 3.3+99.0%112% | 2.4+190%18.1% | 1.1+56.7%13.6% | 1.5*+94.5%— | 1.7+110%15.5% | 0.8+0.1%8.7% | 0.7−3.7%7.6% | 0.8*−21.7%10.2% | 0.8—11.6% | 0.8—9.8% | 0.7—12.8% | 1.0*—13.4% | |
| Cash from operating activities | −41—— | −17*—−581% | −15*—−116% | −22—−269% | 14*—— | −15*—−140% | −17*—−174% | −23—−249% | −0.4*−101%−5.5% | −15*—−223% | −17*—−200% | −18—−317% | 74*—1028% | |
| Capital expenditure | −0.2—— | −0.1*—−4.1% | 0*—0.0% | −0.0—−0.2% | −0.0*—— | −0.0*—−0.4% | 0*—0.0% | 0—0.0% | 0*—0.0% | 0*—0.0% | −0.0*—−0.2% | −0.0—−0.2% | −0.1*—−1.0% | |
| Cash from investing activities | −73—— | 3.5*—119% | −92*−642%−689% | −5.4−182%−65.5% | 21*—— | −158*−746%−1467% | 17*+233%177% | 6.6−61.9%69.9% | −6.7*—−91.0% | 24*—358% | 5.1*—59.8% | 17—299% | −90*—−1252% | |
| Shares issued | 0−100%— | 0*—0.0% | 0*—0.0% | 0−100%0.0% | 0*−100%— | 0*—0.0% | 0*—0.0% | 1.9—20.4% | 2.0*—27.6% | 0*—0.0% | 0*—0.0% | 0—0.0% | 0*—0.0% | |
| Cash from financing activities | 120−37.4%— | 10*−93.9%353% | 109*+30358%813% | 0.1−92.2%1.8% | 0.5*−97.3%— | 172*—1594% | 0.4*−97.1%3.7% | 1.9—20.4% | 17*+84.9%231% | 0*—0.0% | 12*—146% | 0—0.0% | 9.2*—128% | |
| Change in cash | 6.5—— | −3.2*—−109% | 1.2*+96.6%8.7% | −27—−333% | 36*+263%— | −1.5*−116%−13.6% | 0.6*+29.2%6.2% | −15—−159% | 9.9*—134% | 9.2*—135% | 0.5*—5.4% | −1.1—−18.9% | −6.8*—−95.1% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Assembly Biosciences, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Jason A. Okazaki | $2.5 M | $5.5 M | $1.3 M | $218 |
| 2024Jason A. Okazaki | $1.8 M | $2.1 M | $896 K | $101 |
| 2023Jason A. Okazaki | $1.4 M | $1.1 M | $759 K | $63 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Assembly Biosciences, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Acquisition or sale completed 1 · Directors and officers 3 · Material agreement 6 · New debt 1 · Unregistered share sale 3 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 10
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K/A | |
| Acquisition or sale completed | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debt | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2010 | $3 M | No. 1 | $2 to $10 million | 44 | debt, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Assembly Biosciences, Inc.#
1 labor condition applications certified in fiscal 2025 for 1 positions, at a median wage of $233 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Senior Director, Discovery BiologyNatural Sciences Managers | 1 | $233 K |
Where: South San Francisco, CA 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2025 | 1 | 1 | $233 K | 1 |
| FY2021 | 1 | 1 | $88 K | 1 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Assembly Biosciences, Inc.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022 | · | · | · | · | · | · | 30 | · | · | · | · | · | 30 |
| 2020 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 30 people | Restructuring planSEC 8-K | “The Plan includes a reduction of the Company’s workforce by 30 employees, resulting in a total of approximately 70 remaining employees.” | Filing | |
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing |
Source: State WARN notices and SEC 8-K item 2.05
Discuss Assembly Biosciences, Inc.#
2 automatic updates and 0 member comments. Sign in to comment and react.
- Results announced on 12 November 2026automatic update · Nov 12, 2026
Assembly Biosciences, Inc. announced results on 12 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: revenue of $3 million (down 73% from a year earlier) and a net loss of $20 million.
- Mutual funds: 65 funds hold $44 millionautomatic update · Jul 31, 2026
65 mutual funds in 1 country hold shares of Assembly Biosciences, Inc. worth $44 million, about 7.9% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 54 funds added shares and 5 sold; on balance they bought $24 million. Share splits are not counted as trading.
How Assembly Biosciences, Inc. compares in Biotechnology
- Market cap$434 M · higher than 56% of 726
- Revenue$72 M · higher than 64% of 647
- Net margin-16.6% · higher than 63% of 408
- Revenue growth153.5% · higher than 87% of 438
- Price / sales6.5× · lower than 56% of 339
- Price / book2.1× · lower than 57% of 534
- FCF yield-9.5% · higher than 58% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Assembly Biosciences, Inc.🇺🇸 | $434 M | — | -16.6% | +153.5% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 21, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Assembly Biosciences, Inc.? Verify and update this profile — free
Show Assembly Biosciences, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.